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ABSTRACT  
Objectives. Biliary atresia (BA) causes neonatal cholestasis that requires 
hepatoportoenterostomy or liver transplantation (LT) for long-term survival. Nutritional 
optimisation is necessary as sarcopenia and sarcopenic obesity have been associated with 
adverse clinical outcome. Currently, mid upper arm circumference (MUAC) is considered the 
most accurate indicator. The aim of the study was to determine computed tomography (CT)-
based body metrics in infants with BA and to evaluate its correlation with MUAC.   
Methods. We retrospectively analysed all BA infants below two years of age who underwent 
CT as part of LT screening at our hospital between 2006 and 2019. Measured variables were 
indexed with length and included: MUAC, total psoas muscle surface area (tPMSA), cross-
sectional skeletal muscle area (CSMA), and total abdominal fat area. Intraclass correlation 
coefficients and Pearson’s coefficients were calculated. CSMA-to-abdominal fat area ratio 
was divided in quartiles, the lowest quartile group was considered sarcopenic obese. 
Results. Eighty infants with a median age of 4.6 months at LT screening were included. 
Intraclass correlation coefficients were: tPMSA=0.94, CSMA=0.92, and total abdominal fat 
area=0.99. Correlation between MUAC z-score and indices of tPMSA, CSMA, and total 
abdominal fat area were r=0.02, r=0.06, and r=0.43, respectively. The cut-off for sarcopenic 
obesity was CSMA-to-abdominal fat area ratio below 0.93.  
Conclusions. In BA infants, it is possible to determine CT-based body metrics during LT 
screening with very strong interobserver agreement. Poor correlation between CT-based body 
metrics and MUAC suggests that CT-based body metrics provide additional information on 
body composition in BA infants, such as relative muscle mass.  
KEYWORDS  
Sarcopenia; Sarcopenic Obesity; Liver Transplantation; Mid Upper Arm Circumference; 
Nutritional Status 
 
WHAT IS KNOWN? 
 In adults, sarcopenia and sarcopenic obesity at time of screening for liver 
transplantation have been associated with adverse clinical outcomes, both during the 
waiting period and after liver transplantation.  
 Mid upper arm circumference is currently considered as reference standard for 
determining paediatric nutritional status.  
 
WHAT IS NEW? 
 Body composition of young infants with biliary atresia can be reliably determined on 
abdominal computed tomography scans performed as part of liver transplantation 
screening.  
 Computed tomography-based body metrics are poorly correlated with mid upper arm 




BA, biliary atresia 
CT, computed tomography 
KPE, Kasai hepatoportoenterostomy 
LT, liver transplantation 
MUAC, mid upper arm circumference 
tPMSA, total psoas muscle surface area 
CSMA, cross-sectional skeletal muscle area 
PMI, psoas muscle index 
SMI, skeletal muscle index 
AFI, total abdominal fat area index 
L3, third lumbar vertebra 
IQR, interquartile range 
ICC, intraclass correlation coefficient   
m
2
, square metre 
mm
2
, square millimetre  
INTRODUCTION 
Biliary atresia (BA) is a rare disease of infancy in which obliteration and fibrosis of the 
intrahepatic and extrahepatic bile ducts leads to cholestasis and liver fibrosis [1]. Treatment 
of BA primarily consists of Kasai hepatoportoenterostomy (KPE) which results in a 
successful clearance of jaundice in approximately 50% of cases [2,3]. Irrespective of the 
result of the KPE, however, 70-80% of children with BA in Western countries will sooner or 
later develop end-stage liver disease, ultimately necessitating liver transplantation (LT) 
before adulthood [4,5].  
Infants with chronic cholestatic liver disease are prone to malnutrition due to several 
factors: i) intestinal malabsorption of fat and fat-soluble vitamins, ii) abnormalities in the 
metabolism of liver macronutrients’ metabolic pathways, iii) depression of hepatic plasma 
insulin-like growth factors, iv) impeded nutritional intake due to discomfort because of 
ascites, cholestasis and/or organomegaly, and v) increased metabolic demands [6–9]. This 
multifactorial process can lead to neurodevelopmental delay, decreased bone mineralisation, 
loss of muscle mass, and even to paradoxal increase of fat storage, making these infants 
prone to sarcopenia and sarcopenic obesity [10–15].  
In infants with BA, a detailed analysis of the nutritional status has not been easy. A 
variety of measurements have been developed, such as anthropometric parameters including 
weight and mid upper arm circumference (MUAC), assessment of daily intake requirements, 
and laboratory tests such as serum albumin concentration, but their precise interpretation and 
the correlation between these parameters are rather unclear [16]. Weight alone is unreliable 
partly due to possible overestimation caused by hepatosplenomegaly and/or ascites [17,18]. 
MUAC measurement is a non-invasive, inexpensive, and readily available technique, and has 
been described previously to assess growth in infants with BA [17–20]. Therefore, MUAC 
has frequently been considered the gold standard of nutritional status. However, MUAC as 
determinant of nutritional status is imprecise in quantitative analysis of muscle and fat stores, 
as well as in determining their relative distribution within the body [21]. Sarcopenia at the 
time of LT screening, however, is associated with waiting list mortality and early 
posttransplant graft failure and mortality in adults, underlining the importance to obtain 
reliable information that is not provided by current measures, such as MUAC [18,22–24]. 
Even more at risk for adverse clinical outcome after LT are sarcopenic patients with obesity 
[25,26]. Sarcopenia and sarcopenic obesity can be reliably assessed by determining 
abdominal muscle area at computed tomography (CT) scans in adults [27,28]. Total psoas 
muscle surface area (tPMSA) or cross-sectional skeletal muscle area (CSMA) are preferably 
used [29,30]. tPMSA has been shown to change in chronically ill adults and children with 
end-stage liver disease [13,31].  
The aim of this study was to assess whether CT-based body metrics can be 
reproducibly determined in infants with BA. In addition, the correlation between CT-based 
body metrics and MUAC was evaluated.  
 
MATERIALS AND METHODS 
Study population 
All consecutive infants with proven BA younger than two years of age who underwent 
abdominal CT as part of a uniform screening protocol for LT at our hospital between May 
2006 and February 2019 were retrospectively included in the study. In these infants with end-
stage liver disease, CT scans are performed to assess the possibilities of an LT. Our hospital 
is the single national referral centre for KPE and paediatric LT. Infants who fulfilled the 
following criteria were included in the study: i) CT scan and anthropometric measurements 
obtained no more than one week apart from each other, ii) full patient circumference 
displayed on the CT scan at the third lumbar vertebra (L3) level, and iii) full-dose contrast-
enhanced abdominal CT scan in the portal venous phase with a reconstructed slice thickness 
between 1 and 3 millimetre (mm). Infants in whom not the complete body circumference at 
the level of L3 vertebra was displayed at the CT scan, were excluded from the study. The 
study was approved by the local medical ethical committee (reference number 2018/077). 
  
Patient characteristics 
Data were extracted from the electronic patient charts and the prospectively maintained 
Netherlands Study group on Biliary Atresia Registry database. CT images were obtained 
from our Picture Archiving and Communication System. Collected demographic data 
included gender and gestational age. We divided prematurity at birth into gestational age 
categories <37, <35, and <32 weeks. Data needed for LT screening and thus available for the 
study included anatomical subtype of BA, age at KPE, clearance of jaundice, and age at LT 
screening. Anthropometric data included patient length, weight, and MUAC, obtained within 
one week prior to or after CT scan which was performed as part of LT screening. Patient 
length was defined as the distance between head and feet and was rounded to the nearest cm. 
According to our institutional standard of care protocol, to adequately obtain patient length, 
the infant lies down with its head and feet placed flat against a board. The infant legs are 
straightened and the observer uses non-stretchable measuring tape to measure patient length. 
Anthropometric measurements were converted to age-adjusted z-scores [32–34]. Infants were 
classified as having a normal nutritional status (z-score between -2.00 SD and +2.00 SD) or 
an abnormal nutritional status (z-score ≤ -2.00 SD).  
Radiological measurements  
All infants underwent CT imaging of the abdomen as part of LT screening, mainly to 
determine vascular anatomy and to exclude liver lesions. The quantities of intra-abdominal 
fat and skeletal muscle area were determined using standard abdominal contrast-enhanced CT 
scans. Scans were obtained using our standard paediatric liver protocol, with a 512x512 
matrix; slice thickness varied from 1 to 3 mm. Cross-sectional areas (in square millimetre; 
mm
2
) of different tissue compartments were measured on an axial CT slice at the level of L3 
vertebra. Muscle boundaries were manually drawn independently by an abdominal 
radiologist (J.P.P.) and a research fellow (A.L.G.) who was supervised by another abdominal 
radiologist (R.J.d.H.). Within these borders, muscle and fat were defined based on their 
specific differences in attenuation. The thresholds used were -29 to 150 Hounsfield Units 
(HU) for skeletal muscle density, and -190 to -30 HU for adipose tissue [35,36]. tPMSA, 
CSMA, and total abdominal fat area within these contours were automatically segmented by 
in-house developed software (SarcoMeas) [28]. tPMSA was defined as the sum of the left 
and right PMSA. CSMA concerned the sum of the psoas, abdominal wall, and paraspinal 
muscle measurements. Total abdominal fat area was defined as the sum of abdominal and 
subcutaneous adipose tissue areas. Figure 1 shows an example of the determination of CT-
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Quantile-quantile plots were used to determine data distribution. Normally distributed data 
are presented as mean and standard deviation (SD). Non-normally distributed data are 
presented as median and interquartile range [Q1-Q3, IQR]. Categorical data are presented as 
number and percentage. Interobserver agreement was determined by calculating the intraclass 
correlation coefficient (ICC) with a two-way random effects model. Pearson correlation was 
calculated for normally distributed variables to assess bivariate correlation between PMI, 
SMI, and AFI with MUAC z-score. Coefficients were interpreted as poor (less than 0.3), fair 
(0.3 to 0.5), moderate strong (0.6 up to 0.8), or very strong (at least 0.8) [37]. In the absence 
of a widely accepted quantitative definition of sarcopenic obesity, we calculated CSMA-to-
total abdominal fat area ratio. After dividing infants into quartiles according to this ratio, we 
defined the lowest quartile group as sarcopenic obese in concordance to the literature [25,38]. 
SPSS version 23.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.  
 
RESULTS 
Patient characteristics  
A total of 82 BA infants under the age of two, underwent an abdominal CT scan as part of the 
LT screening process. Data of two infants (2%) were not usable, due to incomplete display of 
the abdominal muscle area at the level of L3 vertebra. Data from the remaining 80 infants (52 
girls, 65%) were analysed in the study. The median age at the time of KPE was 59 [IQR: 49, 
75] days. The median age at the time of screening for LT was 4.6 [IQR: 3.6, 5.8] months. At 
LT screening, mean weight z-score was -0.46 (1.12), mean MUAC z-score was -1.35 
(0.88), and mean length z-score was -0.39 (1.04), respectively. Other baseline 
characteristics can be found in Table 1. 
  
CT-based body metrics 
The ICC for determining CT-based body metrics varied between 0.92 and 0.99 (Table 2). The 
mean values of CT-based body metrics and indices of BA infants at the time of LT screening 
can be found in Table 2. Intrasubject correlation coefficient of CSMA with tPMSA was 
moderately strong (r=0.71, Figure, Supplemental Digital Content 1, 
http://links.lww.com/MPG/B892). In the total study population, CT-based body metrics were 
converted to indices and correlated with MUAC z-score. The correlation coefficient of PMI 
with MUAC z-score was poor (r=0.02, Figure 2A). Also, the correlation coefficient of SMI 
with MUAC z-score was poor (r=0.06, Figure 2B). The correlation coefficient of AFI with 
MUAC z-score was fair (r=0.43, Figure 2C). The lowest 25
th
 percentile for the CSMA-to-
total abdominal fat area ratio was 0.93, the correlation coefficient of CSMA with total 
abdominal fat area was fair (r=0.36). All infants in the lowest quartile group had a normal 
nutritional status according to MUAC z-score.  
 
DISCUSSION  
The current study showed that CT-based body metrics can be reproducibly determined in 
infants younger than two years of age with end-stage liver disease due to BA. tPMSA, 
CSMA, and total abdominal fat area can be quantified with very strong interobserver 
agreement with an ICC varying between 0.92 and 0.99. Furthermore, our study demonstrates 
that CT-based body metrics correlated only poor to fair with MUAC. 
The absence of a close relationship between MUAC and inner body composition may 
be explained by the fact that infants with chronic liver disease are susceptible to changes in 
body composition [6,7]. Previous studies in children reported that the accuracy of MUAC in 
determining fat and muscle mass in the body was limited compared to CT or Magnetic 
Resonance Imaging [39,40]. However, validation of MUAC with Dual-energy X-ray 
Absorptiometry showed that MUAC is a good predictor of total body fat, but not of total 
body muscle mass in healthy and chronically ill children [21]. In our cohort, MUAC z-score 
correlated better with AFI compared to SMI. As SMI is most important in determining 
nutritional status, CT-based body metrics provide relevant additional data on inner muscle 
mass.  
For years, MUAC has been considered the gold standard for measuring clinical 
nutritional status in infants with BA [17–20]. However, the value of nutritional assessment 
through MUAC is limited as MUAC is imprecise in quantitative analysis of muscle and fat 
stores [21]. Hurtado-López et al. debate the potential value of arm anthropometrics in 
evaluating nutritional status of infants and toddlers with chronic liver disease by comparing 
total, muscle, and arm fat areas calculated with MUAC and total subcutaneous fat based 
formulas [7]. The arm indicators that separate muscle from fat identified a lower proportion 
of cases with abnormal nutritional status compared to MUAC [7]. Therefore, MUAC z-scores 
should be interpreted with caution. 
Currently, it is still not known which method (i.e., assessment of tPMSA or CSMA) 
should be used to determine sarcopenia [41]. Measurement of tPMSA has been reported as 
simple and convenient, and has been stated to be predictive of morbidities in certain 
conditions [41]. However, others have argued that psoas muscle measurements are not 
representative of CSMA and thus overall sarcopenia [42,43]. In the current study, tPMSA and 
CSMA were only moderately correlated in infants with BA. Therefore, we have decided to 
include CSMA rather than tPMSA in the definition of sarcopenic obesity. However, whether 
CSMA should be preferred over tPMSA to determine sarcopenia and sarcopenic obesity in 
infants, should be assessed in further studies. 
 The cut-off for sarcopenic obesity was a CSMA-to-abdominal fat area ratio below 
0.93. We are the first to report CSMA-to-total abdominal fat area ratios in infants. Mangus et 
al. observed an overall decreased muscle and increased fat mass on CT in children (mean age 
of 7.6 years) with chronic liver disease compared to controls [14]. In the literature on adult 
patients, a low CSMA-to-total abdominal fat area ratio prior to LT, has been found to be 
prognostically unfavourable [25]. A remarkable finding is that all infants in the lowest 
quartile group had a normal nutritional status according to MUAC z-score, suggesting that 
these sarcopenic obese infants nevertheless maintain normal MUAC values. This can be 
explained by the fact that our hospital has an intensive feeding protocol and dietary follow up 
program for these fragile patients. Infants with BA awaiting LT are hypermetabolic in general 
and catabolic during fasting [44]. Therefore, adequate nutrition is essential to prevent that 
caloric intake is stored as fat rather than utilised for reversing the effects of catabolism. 
CSMA-to-total abdominal fat area ratio in infants with BA seems to provide essential 
additional information on inner body composition that is not recognised when using MUAC. 
A decreased CSMA-to-total abdominal fat area ratio may even prompt further investigation 
into: i) the progression of the liver disease of the infant, and ii) a potential acceleration of 
candidacy for transplantation. 
The strong interobserver agreements are in line with the scarce literature on this topic. 
Lurz et al. reported an ICC of 0.99 for the determination of tPMSA in children aged 0 to 18 
years listed for LT [31]. Our findings regarding the poor to fair correlation between CT-based 
body metrics and other traditional parameters of nutritional status are in agreement with 
previous literature that used parameters as weight and albumin level in infants [14,31]. 
Therefore, it can be hypothesised that CT-based body metrics provide novel objective 
nutritional biomarkers for the comprehensive nutritional assessment of children with end-
stage liver disease. Determining accurate markers of inner body composition is important 
because at the time of LT screening, sarcopenia, and even more important sarcopenic obesity, 
are associated with waiting list mortality and early posttransplant graft failure and mortality 
in adults [18,22–26]. In future studies, the potential correlation between CT-based body 
metrics and peri- and post-transplant outcomes in children should be investigated. 
Our study has several limitations. First, due to its retrospective nature, two infants had 
to be excluded due to inadequate display of the complete abdominal muscle area at CT. 
Second, radiation protection has to be kept in mind, and thus, CT-based body metrics seem 
only applicable to infants who have a primary diagnostic reason to perform a CT scan, such 
as determining the vascular anatomy in preparation for an LT. Thus, it is not recommended to 
perform CT scans solely to assess CT-based body metrics. Third, reference values for tPMSA 
of healthy children only exist for ages between 1 and 16 years [45]. As our population 
consisted of infants with a median age of 4.6 months, we could not compare tPMSA values 
with existing validated reference values. Fourth, in our cohort 12% of infants was born 
prematurely. Because it is still unknown whether prematurity leads to changed body 
composition, especially increased fat mass, the relatively large percentage of prematurity 
could have influenced our results [46–48]. Finally, we do not have reliable data on the day to 
day muscle activity of these infants. We speculate that, in the light of the feeding attention 
that these infants receive, the optimisation of the child’s condition could be found in 
“training” of muscle tissue as the only viable option for intervention. 
In conclusion, in infants with BA under the age of two years, it is possible to 
determine CT-based body metrics during LT screening with very strong interobserver 
agreement. The current study shows that CT-based body metrics provide additional, relevant 
information on inner body composition in infants with biliary atresia that is not available 
when using MUAC alone. These findings could be the basis for future studies investigating 
nutritional status by using CT-based body metrics, as well as evaluating their potential impact 
on transplant outcomes. 
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Figure 1 Example of determination of CT-based body metrics on an axial CT slice. 
Transversal determination of CT-based body metrics at the level of the third lumbar vertebra. 
The blue areas represent tPMSA (-29 to 150 HU), and CSMA is represented by the sum of 
the red and blue areas (-29 to 150 HU). Total abdominal fat area is not shown in the image 
but was determined using attenuation values of -190 to -30 HU in the yellow area and in the 
area between the abdominal wall muscles and skin.   
 
  
Figure 2 Correlation between PMI (A), SMI (B), and AFI (C) with MUAC z-score. 
Abbreviations: PMI, psoas muscle index; SMI, skeletal muscle index; AFI, total abdominal 







Table 1 Demographic and clinical characteristics   
Characteristics Cohort (n = 80)      
Gender, n (%) 
    Girls  
 
52 (65%) 
Anatomical pattern of BA, n (%)  
     Type I 
     Type II 
     Type III 
     CBA 
BASM, n (%) 
 
Gestational age in weeks, median [IQR] 
Prematurity at birth <37, <35, and <32 weeks, n (%)  
Age at KPE in days, median [IQR] 
Age <60 days at KPE, n (%)  
Age at screening for LT in months, median [IQR] 
Clearance of jaundice, n (%) 
 
Growth measurements at LT screening 
Weight z-score, mean (SD) 
     z-score ≤-2, n (%) 
MUAC z-score, mean (SD) 
     z-score ≤-2, n (%) 
Length z-score, mean (SD) 
     z-score ≤-2, n (%) 
 
2 (3%) 
4 (5%)   
73 (91%) 
1 (1%)  
4 (5%)  
 
39.6 [37.7, 40.3] 
5 (6%), 4 (5%), 1 (1%) 
59 [49, 75]   
42 (53%) 
4.6 [3.6, 5.8]  
16 (20%)  
 
 
-0.46 (1.12)  
     10 (12%)   
-1.35 (0.88) 
     20 (27%)   
-0.39 (1.04)  
     7 (9%) 
Abbreviations: (C)BA, (cystic) biliary atresia; BASM, biliary atresia structural 
malformation syndrome; IQR, interquartile range; SD, standard deviation; KPE, Kasai 




   
 
Table 2  Overview of determined computed tomography-based body metrics and 
interobserver agreement of each determined variable.  
 Mean (SD) ICC (95% CI) 
tPMSA (mm
2





) 787 (169)  
CSMA (mm
2





) 5864 (949)  
Abdominal fat area (mm
2
)  635 (282) 0.96 (0.94, 0.98) 
Subcutaneous fat area (mm
2
)  1466 (679) 0.99 (0.99, 0.99) 
Total abdominal fat area (mm
2





) 5184 (1762)  
Indices of computed tomography-based body metrics were calculated by correcting 
measurements for length in square metre. Interobserver agreement was determined by 
calculating the ICC.  
Abbreviations: SD, standard deviation; ICC, intraclass correlation coefficient; CI, confidence 
interval; tPMSA, total psoas muscle surface area; CSMA, cross-sectional skeletal muscle 
area; PMI, psoas muscle index; SMI, skeletal muscle index; AFI, total abdominal fat area 
index. 
 
